AstraZeneca Pharma India Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ASTRAZEN BSE: 506820

₹6186.00

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #37 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
AstraZeneca Pharma India Limited (this stock)	15,465	91.2	21.5%	-32.9%	0.58%	78	0	5

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹15,017 Cr

EV / EBITDA

59.8x

EV / Sales

6.17x

Market cap / Sales

6.36x

Earnings yield

1.10%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 692 Cr, up 28.7% YoY.

↓ Negative

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 38 Cr, down 32.1% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	683	51	38	₹15.1700
March 31, 2026	579	58	45	₹17.9500
Dec. 31, 2025	612	47	33	₹13.0400
Sept. 30, 2025	559	73	54	₹21.6900
June 30, 2025	526	75	56	₹22.3300
March 31, 2025	480	78	58	₹23.3000
Dec. 31, 2024	440	42	31	₹
Sept. 30, 2024	408	51	38	₹15.3700
June 30, 2024	388	-15	-12	₹-4.7210
March 31, 2024	383	54	39	₹15.7910
Dec. 31, 2023	306	20	16	₹6.3200
Sept. 30, 2023	311	73	52	₹20.9500
June 30, 2023	295	71	54	₹21.5440

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Total income (before exceptional items)	692	585	617	565	538	497	416	396	392	315	319	304	293
Operating revenue	683	579	612	559	526	480	408	388	383	306	311	295	285
Other income	9	6	5	6	11	16	8	8	9	10	8	8	8
Operating expenses	634	518	567	484	445	394	355	349	334	291	258	228	225
Operating profit	49	61	45	75	81	86	53	38	50	15	53	67	60
Operating profit margin	7.2%	10.5%	7.3%	13.4%	15.4%	18.0%	12.9%	9.8%	12.9%	4.9%	17.0%	22.8%	21.0%
Depreciation	5	6	4	3	17	18	9	4	4	4	4	4	4
Interest	2	2	1	1	1	1	0	0	0	1	1	0	0
Exceptional items, gain / (loss)	-0	-1	1	-5	-0	-6	—	-58	—	—	16	—	-40
Profit before tax	51	58	47	73	75	78	51	-15	54	20	73	71	23
Tax	13	13	14	19	19	20	13	-3	15	5	21	18	6
Net profit	38	45	33	54	56	58	38	-12	39	16	52	54	17
EPS	15.17	17.95	13.04	21.69	22.33	23.30	15.37	-4.72	15.79	6.32	20.95	21.54	6.91
Net profit (TTM)	170	188	201	207	141	124	82	96	162	139	153	133	99
EPS (TTM)	67.85	75.01	80.36	82.69	56.28	49.74	32.76	38.34	64.61	55.72	61.12	53.20	39.72

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	2,276	252	188
March 31, 2025	1,716	156	116
March 31, 2024	1,296	220	162
March 31, 2023	1,003	134	99

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	30.8%	22.8%	2,304^†	—	1,330^†	1,029^†	820^†	826^†	845^†	745^†	584^†	559^†
Operating revenue	31.4%	22.8%	2,276	1,716	1,296	1,003	806^†	814^†	832^†	728^†	572^†	540^†
Other income	—	—	28^†	—	35^†	26^†	15^†	13^†	13^†	16^†	12^†	20^†
Operating expenses	—	—	2,014^†	—	1,111^†	838^†	719^†	678^†	711^†	—	—	—
Operating profit	16.6%	14.1%	262^†	—	185^†	165^†	86^†	135^†	121^†	—	—	—
Operating profit margin	—	—	11.5%^†	—	14.2%^†	16.5%^†	10.7%^†	16.7%^†	14.5%^†	—	—	—
Depreciation	—	—	29^†	—	15^†	16^†	17^†	20^†	19^†	15^†	—	16^†
Interest	—	—	4^†	—	1^†	1^†	1^†	1^†	1^†	—	—	—
Exceptional items, gain / (loss)	—	—	-5^†	—	16^†	-40^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	23.4%	14.7%	252	156	220	134	83^†	127^†	114^†	73^†	44^†	33^†
Tax	—	—	65^†	—	58^†	35^†	21^†	34^†	42^†	18^†	18^†	9^†
Net profit	23.6%	15.0%	188	116	162	99	62^†	93^†	72^†	54^†	26^†	24^†
EPS	23.6%	15.0%	75.01^†	—	64.61^†	39.72^†	24.64^†	37.32^†	28.89^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	11.5%^†	—	14.2%^†	16.5%^†	10.7%^†	16.7%^†	14.5%^†	—	—	—
EBIT margin	11.3%^†	—	17.0%^†	13.4%^†	10.4%^†	15.8%^†	13.8%^†	—	—	—
PBT margin	11.1%	9.1%	16.9%	13.4%	10.3%^†	15.6%^†	13.7%^†	10.0%^†	7.7%^†	6.2%^†
Net margin	8.2%	6.7%	12.5%	9.9%	7.6%^†	11.5%^†	8.7%^†	7.5%^†	4.6%^†	4.5%^†
Interest coverage	57.17x^†	—	165.82x^†	212.80x^†	88.66x^†	117.29x^†	101.26x^†	—	—	—
Dividend payout	42.7%^†	—	24.8%^†	20.1%^†	8.1%^†	5.4%^†	3.5%^†	—	—	—
Earnings retention	57.3%^†	—	75.2%^†	79.9%^†	91.9%^†	94.6%^†	96.5%^†	—	—	—
Current ratio	1.76x	1.91x	—	—	—	—	—	—	—	—
Quick ratio	0.72x	1.13x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.00x	—	—	—	—	—	—	—	—
Return on equity	21.5%	15.0%	—	—	—	—	—	—	—	—
Return on assets	9.4%	7.6%	—	—	—	—	—	—	—	—
Return on capital employed	25.5%^†	—	—	—	—	—	—	—	—	—
Asset turnover	1.14x	1.13x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	-15	19	-92	4	-19
March 31, 2025	65	31	-66	2	64
March 31, 2024	93	22	-44	11	82
March 31, 2023	58	18	-24	9	50
March 31, 2022	101	5	-9	10	91

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,989	873	868	0	0	1,732	982	448	117	1,027
March 31, 2025	1,518	770	765	0	0	1,342	703	536	64	548
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.